TY  - JOUR

T1  - A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

JO  - Blood

PY  - 2013/11/15

AU  - Cook G

AU  - Williams CD

AU  - Cairns DA

AU  - Fletcher M

AU  - Cavenagh JD

AU  - Snowden JA

AU  - Parrish C

AU  - Ashcroft J

AU  - Yong KL

AU  - Cavet J

AU  - Hunter H et al

ED  - 

DO  - DOI: 10.1182/blood.v122.21.765.765

PB  - American Society of Hematology

VL  - 122

IS  - 21

SP  - 765

EP  - 765

Y2  - 2024/12/26

ER  -